Елена Ивановна Тюряева

Елена Ивановна Тюряева

Auto-generated profile, based on publicly available information

Елена Ивановна Тюряева

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2026 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
DRDenis Romanov
Denis Romanov
ETE. I. Turyaeva
E. I. Turyaeva
SNS. N. Novikov
S. N. Novikov
SGS. V. Golub
S. V. Golub
MIM. A. Ilin
M. A. Ilin
МГМ. А. Гетьман
М. А. Гетьман
Aim: to evaluate the efficacy of an oral medical device — a fixed combination of hyaluronic acid, chondroitin sulphate, and the bioadhesive agent poloxamer 407 (Alfasoxx), on the incidence, course, and severity of radiation esophagitis symptoms in patients undergoing external beam radiotherapy for a primary malignancy. Materials and methods. A total of 215 patients were enrolled in the study, of whom 210 were included in the statistical analysis. Patients were divided into two groups: a treatment group (patients with manifestations of radiation esophagitis at study entry) and a prophylaxis group (patients enrolled on the start date of external beam radiotherapy). Seventeen oncologists from nine Russian cities participated in the study. Assessment methods included clinical and demographic evaluation, analysis of the incidence and distribution of radiation esophagitis risk factors, evaluation of radiation esophagitis severity according to CTCAE v. 5.0, assessment of radiation dose delivered to the esophagus, Alfasoxx dosage accounting for compliance, evaluation of the time to radiation esophagitis onset and its duration, analysis of swallowing function using the EAT-10 questionnaire, assessment of overall health-related quality of life using the EORTC QLQ-C30 questionnaire, and monitoring of adverse events. Results. Manifestations of radiation esophagitis were observed in 68.5 % of patients in the prophylaxis group; therefore, radiation esophagitis did not develop in 31.5 % of patients. Compared with the prophylaxis group, patients in the treatment group experienced a more severe course of the disease, with a mean radiation esophagitis severity score of 0.83 ± 0.53 vs. 0.52 ± 0.25 (p < 0.001). The mean EAT-10 score at baseline differed from that in the treatment group. However, from Visit 2 onward, mean scores aligned and demonstrated identical dynamics. A similar distribution was observed for overall quality of life as assessed by the EORTC QLQ-C30 questionnaire. The significant difference observed at the first visit (68.73 ± 15.69 points in the prophylaxis group vs. 58.24 ± 16.04 points in the treatment group; p < 0.001) was leveled by Visit 4 among patients who developed radiation esophagitis (79.96 ± 10.91 points in the prophylaxis group and 81.25 ± 11.03 points in the treatment group). Only one adverse event was identified during Alfasoxx administration: mild nausea after intake. Conclusion. The prophylactic administration of Alfazox concurrently with the initiation of external beam radiotherapy reduces the mean severity of radiation-induced esophagitis and shortens the duration of symptom manifestation.

8 May 2026 in Voprosy onkologii
Verified
Journal Article
Open access
СНСергей Николаевич Новиков
Сергей Николаевич Новиков
ИАИрина Александровна Акулова
Ирина Александровна Акулова
ЕВЕлена Рэмовна Ветлова
Елена Рэмовна Ветлова
АГАртем Рубенович Геворков
Артем Рубенович Геворков
AGAndrey Golanov
Andrey Golanov
СУСергей Владимирович Усычкин
Сергей Владимирович Усычкин
В статье представлены результаты голосования консенсуса экспертов по использованию режимов гипофракционирования дозы у больных со злокачественными новообразованиями различных локализаций, посвященного наиболее актуальным и спорным вопросам лучевого лечения опухолей головного мозга, головы и шеи, рака молочной железы, прямой кишки и предстательной железы. В консенсусе приняли участие 46 ведущих экспертов в области лучевой терапии злокачественных новообразований различных локализаций, проголосовавшие в ходе прямого эфира по 14 вопросам, разделенным на пять блоков. Учитывая возможность использования результатов экспертного голосования при составлении клинических рекомендаций, консенсус считался достигнутым только при 70 %-ном и более совпадении голосов.

20 March 2025 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
APA. V. Polynovsky
A. V. Polynovsky
DKD. V. Kuzmichev
D. V. Kuzmichev
ATAlexey Tryakin
Alexey Tryakin
MCM. V. Chernykh
M. V. Chernykh
OKO. A. Kuznetsova
O. A. Kuznetsova
ZMZ. Z. Mamedli
Z. Z. Mamedli
Background. The development of local recurrences and distant metastases make the problem of treating locally advanced rectal cancer one of the main problems in modern oncoproctology. The organ-preserving approach, sphincter-preserving operations, the role of a complete clinical response to therapy and the low compliance of patients with adjuvant treatment remain in the focus of attention of scientists.Aim. Evaluation of the effectiveness of neoadjuvant sequential induction chemotherapy (CT), chemoradiotherapy (CRT), and CapOx consolidating chemotherapy in patients with locally advanced rectal cancer.Methods. From December 2019 to June 2024, an open-label, randomized phase III study enrolled patients with locally advanced rectal cancer from 3 centers. The inclusion criteria for patients in the study were: histologically confirmed adenocarcinoma, lower and middle rectal cancer, magnetic resonance imaging on a Tesla 3 machine CRM+/4N0-2M0, age 18–75 years, ECOG performance status 0–1. Patients were divided into 2 groups: in the study group, treatment began with 2 courses of induction CT according to the CapOx regimen (oxaliplatin 130 mg/m2 on the 1st day of the course intravenously by drip, capecitabine 2000 mg/m2 twice a day at 12-hour intervals for 14 days, 7 days break). Then, a long course of chemoradiotherapy was carried out: 44 Gy to the areas of regional metastasis, 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. One to two weeks after the end of CRT, two more courses of consolidation CT were carried out according to the CapOx scheme. A control examination was performed 10–12 weeks after the end of CRT. In the control group, a prolonged course of CRT was carried out: ROD 2 Gy, SOD 44 Gy to the areas of regional metastasis and SOD 50–54 Gy to the primary tumor against the background of CT with capecitabine 825 mg/m2 2 times a day per os on the days of radiation therapy. The primary endpoint was 3-year disease-free survival, calculated from the start of treatment to the date of progression and/or death from any cause or the date of last follow-up. Situations when a patient did not die and did not have disease progression were considered as censored events. Survival was calculated using the Kaplan–Meier method.Results. 247 patients were included in the study, 178 (72.1 %) underwent a complete course of treatment, 12 (4.9 %) patients are in the process of treatment or waiting for surgery, 25 (10.1 %) patients were excluded from the study for various reasons: organizational problems, refusal of treatment after randomization, detection of a synchronous tumor or metastases before starting treatment. The remaining 32 (12.9 %) patients did not follow the planned treatment protocol due to progression, death or refusal to continue treatment. The prevalence of acute grade III–V toxicities during preoperative treatment was 6.8 % in the CRT + CT group versus 4.7 % in the CRT group. 19 patients with a complete clinical response refused surgical treatment. 6 (5.8 %) patients in the CRT group and 13 (12.1 %) patients from the group in the CRT + CT group (p = 0.05). The disease free median duration of follow-up in group complete clinical response was 1086 days (36.2 months). Sphincter-sparing operations in the CRT + CT group were performed in 54 (65.8 %) patients versus 41 (53.2 %) in the CRT group (p = 0.05). A subgroup analysis of patients with low rectal cancer showed a significant increase in the frequency of sphincter preservation operations in the main group – 23 (46.9 %) versus 16 (31.4 %) in the control group (p = 0.05). On the basis of the Clavien–Dindo classification, the prevalence of surgical complications was similar between the two groups. The total rate of pCR in the CRT + CT group was 41.2 %, which was significantly higher than that in the CRT group (29.8 %). We demonstrated that patients receiving CRT with neoadjuvant CT were well tolerated, with a compliance rate of 71.2 % than those received adjuvant CT (31.2 %, p = 0.05). In particular, 95 % of the patients in the main group underwent 4 planned courses of neoadjuvant CT. 32.5 % of patients in the chemoradiotherapy group did not start adjuvant CT versus 16 % in the study group. The median duration of follow-up was 36 month. Locoregional recurrence was observed in 5 patients: 3 (2.8 %) in the CRT + CT group (1 patient was operated in a non-specialized clinic, after completion of preoperative treatment within the protocol) and 2 (1.9 %) in the CRT group. There was no significant difference in distant metastases: 20 (19.2 %) patients in CRT group and 21 (19.6 %) patients in the study group. There was no significant difference in dieseas-free survival (75 % in the CRT group versus 77 % in the CRT + CT group). Conclusion. Chemoradiotherapy with preoperative CT followed by surgery was efficacious for locally advanced rectal cancer with a significant increase frequency complete clinical response, sphincter-preserving operations, organpreserving treatment including low rectal cancer and rate patient compliance with CT.

5 November 2025 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
СНСергей Николаевич Новиков
Сергей Николаевич Новиков
ЕТЕлена Ивановна Тюряева
Елена Ивановна Тюряева
РНРоман Владимирович Новиков
Роман Владимирович Новиков
ДСДенис Владимирович Самсонов
Денис Владимирович Самсонов
ПГПавел Юрьевич Гришко
Павел Юрьевич Гришко
АБАлексей Михайлович Беляев
Алексей Михайлович Беляев
Цель. Оценка частоты полных ответов после неоадъювантной сочетанной лучевой терапии с эскалацией дозы на остаточную опухоль. Материалы и методы. В предварительный анализ включены 48 больных с аденокарциномами нижнеампулярного отдела прямой кишки cT2-3N0-2, которым после стандартной дистанционной лучевой терапии проводилось дополнительное облучение оставшейся опухоли с помощью эндоректальной внутриполостной высокодозной брахитерапии (ЭРВБ) в режиме трех фракций по 7 Гр. Маркировка остаточной опухоли выполнялась эндоскопически перед ЭРВБ. Полный клинический ответ оценивался по стандартным критериям: отсутствие пальпируемых изменений, белый рубец при эндоскопии, картина полного ответа при магнитно-резонансной томографии (МРТ). Результаты. Через 8-12 нед. после облучения полный клинический ответ (cCR — clinical complete response) зарегистрирован у 25 из 48 (52 %) больных. Ответ, близкий к cCR, наблюдался в шести случаях. У 17 прооперированных больных полный патоморфологический ответ (pathologic Complete Response — pCR) установлен в семи случаях, т. е. у 41,2 %. В целом суммарный полный ответ (cСR+pСR) достигнут у 32 из 48 (66,6 %) пациентов. У больных сT2N0-1 cСR+pСR отмечался у 16 из 20 (80 %) больных, при более глубокой инвазии (сT3N0-2) — в 17 из 28 случаев (60,7 %). Поздние осложнения со стороны прямой кишки (I-II степени) наблюдались у 29 % неоперированных больных. Тяжелых осложнений (III и более степени) не отмечалось. Выводы. Использование ЭРВБ для дополнительного облучения остаточной опухоли обеспечивает высокую (60,7-80 %) вероятность достижения полного клинического ответа опухоли; значительная частота pCR у больных, которым проведено хирургическое лечение, ставит вопрос о необходимости пересмотра критериев cCR и/или сроков оценки ответа на лечение.